Cancer discovery

Designing immune gene therapy combinations using live CRISPR screening of tumor environment regulators

Updated

Abstract

Multiplexed activation of genes led to enhanced anti-tumor responses in metastatic tumors.

  • A CRISPR activation screen identified CD80, TNFSF14, CXCL10, TNFSF18, TNFSF9, and IFNG as key factors promoting anti-tumor immunity.
  • The combination of TNFSF9 (4-1BBL), IFNG, and IL12B (4II) was found to be a potent therapeutic option.
  • AAV-4II treatment improved antigen presentation, T cell activation, proliferation, cytotoxicity, and tumor infiltration.
  • Preconditioning with AAV-4II enhanced the effectiveness of CAR-T and TCR-T cell therapies against solid tumors in vivo.
  • TME-targeted CRISPRa screening may serve as a rapid approach to develop immune gene therapy combinations.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free